氨甲环酸可降低术前凝血障碍关节置换患者的并发症风险
该回顾性研究纳入2123例术前凝血障碍的初次全关节置换患者,其中240例接受氨甲环酸(TXA),1883例未接受。
要点
- 术前凝血障碍患者接受TXA与90天并发症风险独立降低相关(OR 0.43)。
- TXA组心血管并发症(2.92% vs 12.1%)和伤口并发症(0.0% vs 1.59%)发生率更低。
- TXA与更短住院时间及更低非家庭出院风险相关,死亡率与再入院无差异。
核心结论
- 在术前凝血障碍的关节置换患者中,TXA可降低围手术期并发症和资源利用。
研究设计与样本
- 回顾性研究,纳入2123例初次全关节置换(975膝、1148髋)伴术前凝血障碍患者,其中240例接受TXA,1883例未接受,采用多因素回归分析90天结局。
主要发现
- 两组死亡率和90天再入院率无差异。
关键数值与推荐
- 凝血障碍定义为国际标准化比值>1.2、部分凝血活酶时间>35秒或血小板计数<150,000/μL。
临床怎么用
- 对于术前筛查发现凝血障碍的关节置换患者,可考虑使用TXA以减少并发症和资源利用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preoperative coagulopathy is a risk factor for perioperative blood loss. The antifibrinolytic effects of tranexamic acid (TXA) could negate the association between preoperative coagulopathy and adverse outcomes in patients undergoing total joint arthroplasty (TJA). However, no studies have evaluated this relationship. This study compared the perioperative outcomes of coagulopathic patients undergoing TJA who did and did not receive TXA. METHODS: We retrospectively reviewed 2123 primary TJAs (975 knees and 1148 hips) performed in patients with a preoperative coagulopathy. Coagulopathy was defined as international normalized ratio >1.2, partial thromboplastin time >35 seconds, or platelet count <150,000/μL. TXA was administered in 240 patients and not administered in 1883 patients. Demographics, comorbidities, and surgical details including operative time, blood loss, and thromboprophylaxis agent were recorded. Multivariate regression was used to identify factors associated with 90-day outcomes. RESULTS: Patients who received TXA had less intraoperative blood loss and 2.3 times decreased risk of 90-day complications (odds ratio [OR] 0.43, 95% confidence interval [CI] 0.20-0.85, P = .021), especially cardiovascular (2.92% vs 12.1%, P <.001) and wound complications (0.0% vs 1.59%, P = .042). TXA was also associated with shorter length of stay (beta 0.74, 95% CI 0.67-0.82, P <.001) and decreased risk of nonhome discharge (OR 0.50, 95% CI 0.29-0.83, P = .009). There was no difference in mortality or 90-day readmissions between the groups. CONCLUSION: TXA administration decreased the incidence of perioperative complications and resource utilization in patients undergoing arthroplasty with a preoperative coagulopathy identified on preadmission testing. These findings support the broader adoption of TXA in patients undergoing TJA, particularly when the patient has a preoperative coagulopathy.
引用
- Goh GS, D'Amore T, Lonner JH, et al. Tranexamic Acid is Associated With Decreasing the Risk of Complications in Patients Undergoing Arthroplasty With Preoperative Coagulopathy. J Arthroplasty. 2021. PMID: 34446329. doi:10.1016/j.arth.2021.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。